ArticleMedicine2026
Association between gut epithelial barrier biomarkers and LDL-cholesterol in HIV-infected individuals.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus (HIV) infection causes gut epithelial barrier dysfunction and dyslipidemia. Intestinal fatty acid-binding protein (I-FABP) and regenerating islet-derived protein 3 alpha (REG3α) are markers of gut barrier integrity. We investigated the association between these biomarkers and LDL-cholesterol (LDL-C) in HIV-infected individuals, stratified by immune status and disease duration. This cross-sectional study included 69 HIV-infected adults on antiretroviral therapy. Plasma I-FABP, REG3α, and lipid parameters were measured. Associations were evaluated using Spearman correlation in the total cohort and stratified by cluster of differentiation 4 (CD4) count (<350, 350-500, >500 cells/μL) and disease duration (≤24, 24-48, >48 months). In the total cohort (n = 50 with lipid data), neither I-FABP (rs = -0.044, P = .762) nor REG3α (rs = 0.232, P = .105) showed a significant correlation with LDL-C. However, in patients with CD4 < 350 cells/μL (n = 12), REG3α demonstrated a strong positive correlation with LDL-C (rs = 0.643, P = .024). This association was absent in patients with higher CD4 counts (350-500: rs = 0.393, P = .383; >500: rs = 0.003, P = .985). No significant associations were observed across disease duration strata. REG3α correlates with LDL-C specifically in immunocompromised HIV patients (CD4 < 350 cells/μL), suggesting that gut barrier dysfunction may influence lipid metabolism preferentially in advanced HIV disease. This finding warrants further investigation regarding cardiovascular risk stratification in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.